[1] |
严静, 沈延飞, 脓毒症的诊断及治疗进展[J]. 浙江医学, 2021,43(14),1479-1482.
|
[2] |
王伊帆, 陈燕, 彭劲民, 等. 中国脓毒症流行病学的研究进展[J].中华重症医学电子杂志,2023,9(1),89-94.
|
[3] |
Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock[J].Chest,2009,136(5):1237-1248.
|
[4] |
Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistancethe need for global solutions[J]. Lancet Infect Dis, 2013, 13(12):1057-1098
|
[5] |
Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units[J].JAMA,2009,302(21):2323-2329.
|
[6] |
Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives[J]. Clin Infect Dis,2011,52 Suppl 5(Suppl 5):S397-S428.
|
[7] |
Woodworth KR, Walters MS, Weiner LM, et al. Vital signs:containment of novel multidrug-resistant organisms and resistance mechanisms - united states, 2006-2017[J]. MMWR Morb Mortal Wkly Rep,2018,67(13):396-401.
|
[8] |
Cooper RA, Bjarnsholt T, Alhede M. Biofilms in wounds: a review of present knowledge[J]. J Wound Care, 2014,23(11): 570, 572-574,576-580.
|
[9] |
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP/SCCM consensus conference committee.american college of chest physicians/society of critical care medicine[J].Chest,1992,101(6):1644-1655.
|
[10] |
American college of chest physicians/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J].Crit Care Med,1992,20(6):864-874.
|
[11] |
Bone RC, Fisher CJ Jr, Clemmer TP, et al. Sepsis syndrome: a valid clinical entity.methylprednisolone severe sepsis study group[J].Crit Care Med,1989,17(5):389-393.
|
[12] |
中国严重脓毒症/脓毒性休克治疗指南(2014)[J]. 全科医学临床与教育,2015,13(4):365-367.
|
[13] |
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock:2012[J].Crit Care Med,2013,41(2):580-637.
|
[14] |
Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):762-774.
|
[15] |
Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):775-787.
|
[16] |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):801-810.
|
[17] |
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study[J]. Lancet, 2020,395(10219):200-211.
|
[18] |
Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in european intensive care units: results of the SOAP study[J]. Crit Care Med,2006,34(2):344-353.
|
[19] |
王伊帆, 陈燕, 彭劲民, 等, 中国脓毒症流行病学的研究进展[J].中华重症医学电子杂志,2023,9(1):89-94.
|
[20] |
Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in england, wales, and northern ireland[J]. Crit Care Med, 2003, 31(9):2332-2338.
|
[21] |
Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference:definitions for sepsis and organ dysfunction in pediatrics[J].Pediatr Crit Care Med,2005,6(1):2-8.
|
[22] |
Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008[J]. Intensive Care Med, 2008, 34(1):17-60.
|
[23] |
Kümmerer K. Antibiotics in the aquatic environment-a reviewpart II[J].Chemosphere,2009,75(4):435-441.
|
[24] |
Grenni P, Ancona V, Caracciolo AB. Ecological effects of antibiotics on natural ecosystems: a review[J]. Microchem J, 2018,(136):25-39.
|
[25] |
Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015[J]. Proc Natl Acad Sci U S A, 2018, 115(15):E3463-E3470.
|
[26] |
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis[J]. Lancet,2022,399(10325):629-655.
|
[27] |
Van Boeckel TP, Gandra S, Ashok A,et al. Global antibiotic consumption 2000 to 2010:an analysis of national pharmaceutical sales data[J].Lancet Infect Dis,2014,14(8):742-750.
|
[28] |
国家卫生健康委员会.中国抗菌药物管理和细菌耐药现状报告(2018)[M].北京:中国协和医科大学出版社,2018:73.
|
[29] |
Zhang QQ, Ying GG, Pan CG, et al. Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance[J].Environ Sci Technol,2015,49(11):6772-6782.
|
[30] |
Davies J, Davies D. Origins and evolution of antibiotic resistance[J].Microbiol Mol Biol Rev,2010,74(3):417-433.
|
[31] |
隋倩雯,张俊亚,魏源送,等.畜禽养殖过程抗生素使用与耐药病原菌及其抗性基因赋存的研究进展[J]. 生态毒理学报,2015,10(5):20-34.
|
[32] |
Pei N, Sun W, He J, et al. Genome-wide association study of klebsiella pneumoniae identifies variations linked to carbapenems resistance[J].Front Microbiol,2022(13):997769.
|
[33] |
杜金洁,胡鹏,ESKAPE病原菌感染引起脓毒症的研究[J].医学信息,2019,32(21):33-36.
|
[34] |
Nakano Y, Murata M, Matsumoto Y, et al. Clinical characteristics and factors related to infection with SCCmec type II and IV methicillin - resistant staphylococcus aureus in a Japanese secondary care facility: a single-center retrospective study[J]. J Glob Antimicrob Resist,2022(31):355-362.
|
[35] |
高倩倩,殷杏,祝俊英,等.碳青霉烯类耐药肺炎克雷伯菌的分子特征[J].中国感染与化疗杂志,2018,18(1):53-57.
|
[36] |
戴仲秋,康梅,马莹,等.四川大学华西医院2006 年-2015 年肠杆菌科细菌分布及耐药特点分析[J].华西医学,2018,33(3):289-293.
|
[37] |
陈永生,付斌,郑永先,等.多药耐药革兰阴性菌感染脓毒症患者TLR4 及内毒素变化与病情发展的关系[J].中华医院感染学杂志,2022,32(23):3542-3546.
|
[38] |
El-Mahallawy HA, Hassan SS, El-Wakil M, et al. Bacteremia due to ESKAPE pathogens:an emerging problem in cancer patients[J].J Egypt Natl Canc Inst,2016,28(3):157-162.
|
[39] |
Lee CR, Lee JH, Park M, et al. Biology of acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options[J].Front Cell Infect Microbiol,2017(7):55.
|
[40] |
Ramette A, Kronenberg A. Prevalence of carbapenem-resistant acinetobacter baumannii from 2005 to 2016 in switzerland[J].BMC Infect Dis,2018,18(1):159.
|
[41] |
邹颖,徐晓刚,郭庆兰,等.多重耐药不动杆菌属血流感染74例临床分析[J].中国感染与化疗杂志,2014,14(3):190-195.
|
[42] |
Bodro M, Sabé N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solidorgan transplant recipients[J]. Transplantation, 2013, 96(9): 843-849.
|
[43] |
余跃天,马朋林,重症监护病房多重耐药菌防控:指南与实践[J].中华医学杂志,2019(25):1945-1948.
|
[44] |
Bodro M, Gudiol C, Garcia - Vidal C, et al. Epidemiology,antibiotictherapy and outcomes of bacteremia caused by drugresistant ESKAPE pathogens in cancer patients[J]. Support Care Cancer,2014,22(3):603-610.
|
[45] |
史静,陈晴毅,徐绣宇,等.碳青霉烯耐药肠杆菌科细菌感染脓毒症患者的危险因素和耐药性[J]. 中华医院感染学杂志,2022,32(23):3547-3551.
|
[46] |
Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution[J]. Curr Opin Microbiol,2015(27):1-9.
|
[47] |
郑丹文, 黎扬嵋, 多重耐药菌血行感染的预后危险因素分析[J].临床急诊杂志,2018,19(5):299-302.
|
[48] |
Deng C, Zhao L, Yang Z, et al. Targeting HMGB1 for the treatment of sepsis and sepsis - induced organ injury[J]. Acta Pharmacol Sin,2022,43(3):520-528.
|
[49] |
万印利,胡萍,赵立群,急诊内科脓毒症患者的炎症因子表达、病原菌分布及其预后分析[J].海南医学,2022,33(8):983-986.
|
[50] |
Zhang H, Wang Y, Qu M, et al. Neutrophil, neutrophil extracellular traps and endothelial cell dysfunction in sepsis[J].Clin Transl Med,2023,13(1):e1170.
|
[51] |
徐策,葛新,宦陟榕,脓毒症患者血清HBP 水平与常规炎症标志物相关性及联合HBP 清除率对不良预后的预测价值[J].临床急诊杂志,2021,22(9):582-586.
|
[52] |
Botelho J,Grosso F,Peixe L.Antibiotic resistance in pseudomonas aeruginosa-mechanisms, epidemiology and evolution[J]. Drug Resist Updat,2019(44):100640.
|
[53] |
Pang Z, Zhu Q. Traditional Chinese medicine is an alternative therapeutic option for treatment of pseudomonas aeruginosa infections[J].Front Pharmacol,2021(12):737252.
|
[54] |
孙爽,张雪,刘漪漩,等.重症颅脑损伤患者多药耐药菌感染病原学及危险因素[J].中华医院感染学杂志,2023,33(6):871-874.
|
[55] |
刘彦妤,岳慧杰,陈晨,等.肾移植受者围手术期感染危险因素及预防用抗菌药物合理性的分析[J]. 医学研究生学报, 2020,33(11):1181-1186.
|
[56] |
Agweyu A,Kibore M,Digolo L,et al.Prevalence and correlates of treatment failure among kenyan children hospitalised with severe community - acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines[J].Trop Med Int Health,2014,19(11):1310-1320.
|
[57] |
Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: time for change[J].Lancet,2013,381(9868):774-775.
|
[58] |
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013, 39(2):165-228.
|
[59] |
Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference[J]. Crit Care Med,2003,31(4):1250-1256.
|
[60] |
Nolte FS, Gauld L, Barrett SB. Direct comparison of alere i and cobas liat influenza a and b tests for rapid detection of influenza virus infection[J].J Clin Microbiol,2016,54(11):2763-2766.
|
[61] |
梅骁乐,陈威巍,中国呼吸道腺病毒流行趋势及临床诊疗进展[J].中国临床医生杂志,2019,47(10):1159-1161.
|
[62] |
梁建琴,切实关注耐药结核病的早期发现、早期诊断及规范治疗[J].中国医刊,2019,54(9):929-932.
|
[63] |
Bacconi A, Richmond GS, Baroldi MA, et al. Improved sensitivity for molecular detection of bacterial and candida infections in blood[J].J Clin Microbiol,2014,52(9):3164-3174.
|
[64] |
陈龙,董亚晨,赵建华,等.宏基因组测序[J].高科技与产业化,2017(5):40-45.
|
[65] |
Blauwkamp TA, Thair S, Rosen MJ, et al. Analytical and clinical validation of a microbial cell - freeDNA sequencing test for infectious disease[J].Nature Microbiology,2019,4(4):663-674.
|
[66] |
Ye M, Wei W, Yang Z, et al. Rapid diagnosis of propionibacterium acnes infection in patient with hyperpyrexia after hematopoietic stem cell transplantation by next-generation sequencing:a case report[J].BMC Infect Dis,2016(16):5.
|
[67] |
Parize P, Muth E, Richaud C, et al. Untargeted next-generation sequencing - based first - line diagnosis of infection in immunocompromised adults: amulticentre, blinded, prospective study[J].Clin Microbiol Infect,2017,23(8):574.
|
[68] |
Williams SH, Cordey S, Bhuva N, et al. Investigation of the plasma virome from cases of unexplained febrile illness in tanzania from 2013 to 2014: a comparative analysis between unbiased and VirCapSeq - VERT high - throughput sequencing approaches[J].mSphere,2018,3(4):e00311-e00318.
|
[69] |
王帆,文力,温伟,分子生物学时代脓毒症病原诊断的现状和挑战[J].中国临床医生杂志,2021,49(8):911-913.
|
[70] |
Tsalik EL,Jones D,Nicholson B,et al.Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis[J].J Clin Microbiol,2010,48(1):26-33.
|
[71] |
Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever,endocarditis, and kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group[J].Circulation,2007,116(15):1736-1754.
|
[72] |
Hartwig W, Werner J, Müller CA, et al. Surgical management of severe pancreatitis including sterile necrosis[J]. J Hepatobiliary Pancreat Surg,2002,9(4):429-435.
|
[73] |
李勇,抗生素降阶梯疗法治疗重症肺炎的临床效果观察[J].广西医学,2017,39(7):1098-1099.
|
[74] |
Kew J, Rees GL, Close D, et al. Multiplanar reconstructed computed tomography images improves depiction and understanding of the anatomy of the frontal sinus and recess[J].Am J Rhinol,2002,16(2):119-123.
|
[75] |
WHO. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level[EB/OL].(2016-11-01)[2024-05-18].https://www.who.int/publications/i/item/9789241549929.
|
[76] |
Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the centers for disease control and prevention[J]. Clin Infect Dis, 2014, 59 Suppl 3(Suppl 3): S97-S100.
|
[77] |
刘春峰,脓毒症抗生素治疗策略[J].中国实用儿科杂志,2017,32(6):439-443.
|
[78] |
张黎,刘正印,常见侵入性装置相关感染的抗生素使用及疗程[J].中国临床医生,2011,39(11):3-6.
|
[79] |
Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia[J]. Am J Respir Crit Care Med,2001,163(6):1371-1375.
|
[80] |
Chastre J,Wolff M,Fagon JY,et al.Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial[J].JAMA,2003,290(19):2588-2598.
|
[81] |
Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, shortcourse levofloxacin for community-acquired pneumonia: a new treatment paradigm[J].Clin Infect Dis,2003,37(6):752-760.
|
[82] |
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia[J]. N Engl J Med,1997,336(4):243-250.
|
[83] |
姚开虎,杨永弘.预防儿童肺炎链球菌疾病专家共识[J].中国实用儿科杂志,2009,24(8):602-605.
|
[84] |
Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients[J]. N Engl J Med, 2009,360(13):1283-1297.
|
[85] |
Tacconelli E,Carrara E,Savoldi A,et al.Discovery,research,and development of new antibiotics:the WHO priority list of antibioticresistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3):318-327.
|